Another inhibitory ligand, PD-L2, is the second ligand of the PD-1 receptor to inhibit T-cell function [7] and, in consequence, both PD-L1 and PD-L2 expression is predictive of a response to anti-PD-1 therapy in cancers [8,9,10]. Here, CD274 is linked to cancer.